Most human cancers involve multiple genetic changes, including activat
ion of oncogenes such as Ki-ras-2 (Kras2) and inactivation of any one
of a number of tumor suppressor genes such as p53 and members of the r
etinoblastoma (Rb) regulatory axis. As part of an ongoing project to d
etermine how in utero exposure to chemical carcinogens affects the mol
ecular pathogenesis of murine lung tumors, the p53 and p16(Cdkn2a) gen
es were analyzed by using paraffin-embedded lung tissues from mice tre
ated transplacentally with 3-methylcholanthrene. Single-strand conform
ation polymorphism analysis of exons 5-8 of the p53 gene, as well as t
heir flanking introns, demonstrated an absence of mutations at this ge
ne locus. However, a genetic polymorphism was identified at nt 708 in
intron 4 of the DBA/2 strain of mice 5 bp downstream of a 3' branching
-point splice signal. Analysis of exons 1 and 2 of the Cdkn2a gene by
single-strand conformation polymorphism and sequence analyses revealed
mutations in exon 2 in 7% of the tumors examined. Tumor 23-1 exhibite
d a CAC-->TAC transition at nt 301 (His(74)-->Tyr(74)) and tumor 36-1
exhibited a GGG-->GAG transition at nucleotide 350 (Gly(90)-Glu90). No
rthern blot analysis of 14 of the larger tumors showed a marked decrea
se in the levels of Rb RNA expression. Immunohistochemical analysis re
vealed a spectrum of pRb expression, with the smaller adenomas showing
moderate numbers of nuclei with heterogeneous staining for pRb in con
trast with a highly reduced or near-complete absence of expression in
the nuclei of larger tumors with features of adenocarcinomas. The low
incidence of mutations at tumor suppressor loci suggested that inactiv
ation of tumor suppressor genes was a late event in murine lung tumor
pathogenesis. The identification of both mutations at the CdknZa gene
locus and reduced levels of Rb expression combined with previous studi
es demonstrating a high incidence of mutated Kras2 alleles in these tu
mors implies that alterations of the Rb regulatory axis, in combinatio
n with mutation of Kras2, may be the preferred pathway for the pathoge
nesis of pulmonary tumors in transplacentally exposed mice. (C) 1998 W
iley-Liss, Inc.